9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CD4 + T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Immune inhibitory receptors play an important role in chronic infections. However, little is known about their role in hepatitis B virus (HBV) infection. Here, we analyzed the relationship between programmed death-1 (PD-1) and lymphocyte activation gene-3 (LAG-3) expression on CD4 + T cells and HBV disease progression.

          Results

          PD-1 and LAG-3 expression was significantly higher on CD4 + T cells from HBV patients than on those from the HCs. In addition, a significant positive correlation was found between the PD-1 and LAG-3 expression levels and the ALT(alanine aminotransferase) level. CD4 + T cell function was inhibited by high PD-1 and LAG-3 levels, and CD4 + T cells with high PD-1 and LAG-3 expression lost the ability to secrete IFN-γ, IL-2 and TNF-α. Furthermore, blockade of the PD-1 and LAG-3 pathways reversed the damage to CD4 + T cell proliferation and cytokine secretion.

          Conclusions

          CD4 + T cell exhaustion during chronic HBV had high PD-1 and LAG-3 expression and the absence of helper T cell cytokines, including IFN-γ, IL-2 and TNF-α. After blocking PD-L1 and LAG-3, CD4 + T cell function in chronic hepatitis B patients was partially restored.

          Related collections

          Most cited references33

          • Record: found
          • Abstract: found
          • Article: not found

          A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

          Harnessing an antitumor immune response has been a fundamental strategy in cancer immunotherapy. For over a century, efforts have primarily focused on amplifying immune activation mechanisms that are employed by humans to eliminate invaders such as viruses and bacteria. This "immune enhancement" strategy often results in rare objective responses and frequent immune-related adverse events (irAEs). However, in the last decade, cancer immunotherapies targeting the B7-H1/PD-1 pathway (anti-PD therapy), have achieved higher objective response rates in patients with much fewer irAEs. This more beneficial tumor response-to-toxicity profile stems from distinct mechanisms of action that restore tumor-induced immune deficiency selectively in the tumor microenvironment, here termed "immune normalization," which has led to its FDA approval in more than 10 cancer indications and facilitated its combination with different therapies. In this article, we wish to highlight the principles of immune normalization and learn from it, with the ultimate goal to guide better designs for future cancer immunotherapies.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Chronic hepatitis B.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Effector and memory CTL differentiation.

              Technological advances in recent years have allowed for an ever-expanding ability to analyze and quantify in vivo immune responses. MHC tetramers, intracellular cytokine staining, an increasing repertoire of transgenic and "knockout" mice, and the detailed characterization of a variety of infectious models have all facilitated more precise and definitive analyses of the generation and function of cytotoxic T lymphocytes (CTL). Understanding the mechanisms behind the differentiation of effector and memory CTL is of increasing importance to develop vaccination strategies against a variety of established and emerging infectious diseases. This review focuses on recent advances in our understanding of how effector and memory CTL differentiate and survive in vivo in response to viral or bacterial infection.
                Bookmark

                Author and article information

                Contributors
                86-571-87236381 , chenyuzy@zju.edu.cn
                Journal
                BMC Immunol
                BMC Immunol
                BMC Immunology
                BioMed Central (London )
                1471-2172
                7 August 2019
                7 August 2019
                2019
                : 20
                : 27
                Affiliations
                [1 ]ISNI 0000 0004 1759 700X, GRID grid.13402.34, Department of Laboratory Medicine, Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, First Affiliated Hospital, College of Medicine, , Zhejiang University, ; 79 Qingchun Road, Hangzhou, 310003 China
                [2 ]ISNI 0000 0004 1759 700X, GRID grid.13402.34, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, , Zhejiang University, ; 79 Qingchun Road, Hangzhou, 310003 China
                Author information
                http://orcid.org/0000-0003-3864-8446
                Article
                309
                10.1186/s12865-019-0309-9
                6686459
                31390978
                ec4504dd-a570-4a34-af97-64198fc28fa0
                © The Author(s). 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 30 October 2018
                : 29 July 2019
                Funding
                Funded by: Scientific Technology Projects of Health and Family Planning Commission of Zhejiang Province
                Award ID: 2017KY066
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 81672092
                Award Recipient :
                Funded by: Major National S&T Projects for Infectious Diseases
                Award ID: 2017ZX10202201-002-004
                Award Recipient :
                Funded by: Natural Science Foundation of Zhejiang Province
                Award ID: LY15H030012
                Award Recipient :
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2019

                Immunology
                cd4+ t cells,chronic hbv infection,inhibitory molecules,programmed death 1 (pd-1),lymphocyte activation gene-3 (lag-3),cytokine

                Comments

                Comment on this article